 | • レポートコード：MRC2203A041 • 出版社/出版日：Mordor Intelligence / 2022年1月 • レポート形態：英文、PDF、112ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医療 |
| Single User | ￥703,000 (USD4,750) | ▷ お問い合わせ |
| Site Licence | ￥962,000 (USD6,500) | ▷ お問い合わせ |
| Corporate License | ￥1,295,000 (USD8,750) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| Mordor Intelligence社は、世界の脳腫瘍診断市場規模が、年平均3.3％成長すると予測しています。本市場調査レポートでは、脳腫瘍診断の世界市場について調査・分析し、イントロダクション、調査手法、エグゼクティブサマリー、市場動向、診断種類別（画像検査、腰椎穿刺、生検、分子検査、その他）分析、腫瘍種類別（転移性、髄膜腫、膠芽腫、下垂体腺腫、その他）分析、エンドユーザー別（病院、診断センター、その他）分析、地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米）分析、競争状況、市場機会・将来傾向など、以下の構成でまとめました。 ・イントロダクション ・調査手法 ・エグゼクティブサマリー ・市場動向 ・世界の脳腫瘍診断市場規模：診断種類別（画像検査、腰椎穿刺、生検、分子検査、その他） ・世界の脳腫瘍診断市場規模：腫瘍種類別（転移性、髄膜腫、膠芽腫、下垂体腺腫、その他） ・世界の脳腫瘍診断市場規模：エンドユーザー別（病院、診断センター、その他） ・世界の脳腫瘍診断市場規模：地域別（北米、ヨーロッパ、アジア太平洋、中東・アフリカ、南米） ・競争状況（GE Healthcare、Koninklijke Philips N.V.、Siemens Healthcare GmbH、…） ・市場機会・将来傾向 |
The brain tumor diagnostics market studied was anticipated to grow with a CAGR of 3.3%, during the forecast period. The significant factor attributing market growth is the rising incidence of brain cancer and increasing technological advancement in diagnostics devices. The increasing geriatric population across the globe also drives the brain tumor diagnostics market. There are more than 79,000 new cases of primary brain tumors diagnosed in 2019, with about one percent (around 23,880) of which were malignant, as per the American Cancer Society. The median age of diagnosis is 59 however most often occur in children and older people. Exposure to ionizing radiation, both medical (disease treatment) and atomic bomb exposure, has been linked with the occurrence of some forms of major brain tumors, including gliomas, meningiomas, and sarcomas, specifically when the exposure occurred during childhood. All these factors are expected to boost the growth of the brain tumor diagnostics market during the forecast period.
Key Market Trends
MRI segment is Expected to Hold the Largest Market Share in the Brain Tumor Diagnostics Market
- Dominant share is retained by the MRI segment owing to the attributes such as high application in the diagnosis of brain tumor. The rising prevalence of brain cancer cases across the world is expected to drive the demand for brain tumor diagnostics market over the forecast period. As per the Central Brain Tumor Registry of the United States report 2018, an additional 86,970 new cases of primary malignant and non-malignant brain and other CNS tumors are anticipated to be diagnosed in the United States in 2019. It represents an estimated 26,170 primary malignants and 60,800 non-malignants anticipated to be diagnosed in the United States in 2019.
- Additionally, development is fueled by developments in scanning technologies such as open MRI devices, development in software, and superconductive magnets. Advances in contrasting agents such as the gadolinium-DTPA, paramagnetic contrasting agents are used as an intravenous injection to provide clear, reliable, and precise pictures in 20 minutes to 1 hour.
North America Dominates the Market and Expected to do Same in the Forecast Period
North America is expected to maintain its supremacy in the overall brain tumor diagnostics market, throughout the forecast period. This is owing to factors such as the rising prevalence of brain cancer and the growing geriatric population. In the United States in 2018, the incidence of all primary malignant and non-malignant brain and other CNS tumors is 23.03 cases per 100,000, for a total count of 392,982 tumor incidences. Moreover, the excellently-established healthcare infrastructure coupled with rising awareness regarding advanced technologies among the population in this region and strong acceptance of developed diagnostics methods are also some of the key factors ensuring the dominance of the region.
Competitive Landscape
The brain tumor diagnostics market is competitive and consists of a few major players. In terms of market share, few of the major players are currently dominating the market. And some prominent players are vigorously making collaborations, acquisition, and launching new products with the other companies to consolidate their market positions across the globe. Some of the companies which are currently dominating the market are GE Healthcare, Koninklijke Philips N.V., Siemens Healthcare GmbH, Fujifilm Corporation, and Hitachi, Ltd.
Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
1 INTRODUCTION
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2 RESEARCH METHODOLOGY
3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Increasing Prevalence of Neurological Disorders and Cancers
4.2.2 Rising Number of Smokers
4.3 Market Restraints
4.3.1 Heavy costs associated with diagnosis
4.4 Porter’s Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION
5.1 By Diagnostic Type
5.1.1 Imaging Test
5.1.1.1 MRI
5.1.1.2 CT Scan
5.1.1.3 Other
5.1.2 Lumbar Puncture
5.1.3 Biopsy
5.1.4 Molecular Testing
5.1.5 Others
5.2 By Tumor Type
5.2.1 Metastatic
5.2.2 Meningioma
5.2.3 Glioblastoma
5.2.4 Pituitary Endoma
5.2.5 Others
5.3 By End User
5.3.1 Hospitals
5.3.2 Diagnostics Centers
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 GE Healthcare
6.1.2 Koninklijke Philips N.V.
6.1.3 Siemens Healthcare GmbH
6.1.4 Fujifilm Corporation
6.1.5 Hitachi, Ltd.
6.1.6 Hologic, Inc.
6.1.7 NantOmics
6.1.8 Thermo Fisher Scientific
7 MARKET OPPORTUNITIES AND FUTURE TRENDS